(Sharecast News) - Drugmaker GSK said on Friday that the US Food and Drug Administration had approved its Blenrep asset in combination with bortezomib and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma.
GSK said the approval covers patients who have received at least two prior lines...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE